394 related articles for article (PubMed ID: 8241988)
1. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
Winston DJ; Ho WG; Bartoni K; Champlin RE
Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
[TBL] [Abstract][Full Text] [Related]
2. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
3. Prevention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening.
Miller WJ; McCullough J; Balfour HH; Haake RJ; Ramsay NK; Goldman A; Bowman R; Kersey J
Bone Marrow Transplant; 1991 Mar; 7(3):227-34. PubMed ID: 1647829
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.
von Bueltzingsloewen A; Bordigoni P; Witz F; Bene MC; Schmitt C; Lacour B; Sommelet D
Bone Marrow Transplant; 1993 Sep; 12(3):197-202. PubMed ID: 8241976
[TBL] [Abstract][Full Text] [Related]
7. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
8. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
[TBL] [Abstract][Full Text] [Related]
10. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
[TBL] [Abstract][Full Text] [Related]
11. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
13. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
[TBL] [Abstract][Full Text] [Related]
15. CMV infections in bone marrow transplanted patients--evaluation of prophylaxis with Cytotect (CMV hyperimmuneglobulin).
Zintl F; Färber I; Hermann J; Fuchs D; Prager J; Wutzler P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(3-4):557-64. PubMed ID: 2480308
[TBL] [Abstract][Full Text] [Related]
16. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.
Winston DJ; Gale RP
Bone Marrow Transplant; 1991 Jul; 8(1):7-11. PubMed ID: 1655140
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.
Bass EB; Powe NR; Goodman SN; Graziano SL; Griffiths RI; Kickler TS; Wingard JR
Bone Marrow Transplant; 1993 Sep; 12(3):273-82. PubMed ID: 8241987
[TBL] [Abstract][Full Text] [Related]
18. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation.
Funada H; Harada M; Yoshida T; Hattori K
Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():519-30. PubMed ID: 6097710
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
[TBL] [Abstract][Full Text] [Related]
20. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
